Press Coverage

All press coverage

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With Morphosys

Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company’s capabilities to help enable the development and potential approvals of important cancer treatments.

This funding partnership is anchored by Royalty Pharma’s acquisition of MorphoSys’ rights to receive future royalties on Janssen’s Tremfya (guselkumab). Tremfya is an anti interleukin (IL)-23, approved for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis and is also in clinical development for ulcerative colitis and Crohn’s disease. In 2020, Tremfya generated sales of $1.347 billion.



Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma. Goldman Sachs Bank Europe SE acted as financial advisor to MorphoSys and Skadden, Arps, Slate, Meagher & Flom LLP acted as its legal advisor. Centerview Partners LLC and PJT Partners acted as financial advisors to Constellation and Wachtell, Lipton, Rosen & Katz acted as its legal advisor.

This text is a press release from Royalty Pharma. The full text version of the article can be found here:

Furthermore, we are pleased about the great response to the closing of the deal in the daily press. Further articles and comments can be found here: „Morphosys: Milliardendeals mit Constellation Pharmaceuticals und Royalty Pharma“ (only available in German) „ROUNDUP/Milliardendeal: Morphosys übernimmt US-Biotechfirma – Aktie verliert“ (only available in German) (only available in German) (only available in German)

EndpointsNews via „UPDATED: MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact“

Evaluate Vantage by „Morphosys mortgages its future” “Wachtell, Skadden Guide MorphoSys’ $1.7B Cancer Co. Buy”

MarketsInsider by